journal
https://read.qxmd.com/read/37740588/phase-1b-dose-finding-study-of-rituximab-lenalidomide-and-ibrutinib-r2i-in-patients-with-relapsed-refractory-mantle-cell-lymphoma
#1
JOURNAL ARTICLE
Andrew Ip, Alessandra Petrillo, Alexandra Della Pia, Geeny G Lee, Sarvarinder Gill, Tony Varughese, Joshua Zenreich, Martin Gutierrez, Jiayu Zhang, Jaeil Ahn, Vishnu Bharani, Ava S Nejad, Lauren Pascual, Tatyana A Feldman, Lori A Leslie, Andre H Goy
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients ( n  = 25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1-21) and ibrutinib 560 mg (days 1-28) of 28-day cycles. The MTD for lenalidomide was 20 mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%)...
September 23, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37732615/comparative-analysis-of-hypomethylating-agents-as-maintenance-therapy-after-allogeneic-hematopoietic-stem-cell-transplantation-for-high-risk-acute-leukemia
#2
JOURNAL ARTICLE
Li Li, Ran Zhang, Weijie Cao, Zhilei Bian, Yang Qin, Rong Guo, Suping Zhang, Yingnan Peng, Dingming Wan, Wang Ma
We retrospectively analyzed the outcomes of 136 consecutive patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center. Among them, 76 cases used hypomethylating agents (decitabine, n  = 40; azacitidine, n  = 36) as post-transplant maintenance therapy, whereas 60 contemporaneous patients did not adopt maintenance therapy. The 3-year incidences of relapse in two groups were 16.6% and 39.2% ( p  = .001). The 3-year OS and DFS in maintenance group were 84...
September 21, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37732614/interruption-of-btk-inhibitor-improves-response-to-sars-cov-2-booster-vaccination-in-patients-with-cll
#3
JOURNAL ARTICLE
Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun
B-cell targeted therapies, including anti-CD20 monoclonal antibodies (mAb) and Bruton's tyrosine kinase inhibitors (BTKi), further suppress antibody (Ab) response to vaccines in patients with chronic lymphocytic leukemia (CLL). We conducted a prospective cohort study of SARS-CoV-2 vaccination in 81 CLL patients receiving BTKi ( n  = 54), venetoclax (VEN, n  = 9), or who were treatment naïve (TN, n  = 18). Anti-spike Ab were detected in 53% of patients on BTKi post-primary series and 84% post-booster, 57% of patients on VEN post-primary series and 50% post-booster, and 67% of TN patients post-primary series and 87% post-booster...
September 21, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37732602/real-world-adherence-and-discontinuation-among-medicare-beneficiaries-initiating-venetoclax-vs-btkis-in-relapsed-refractory-chronic-lymphocytic-leukemia
#4
JOURNAL ARTICLE
Scott F Huntington, Beenish S Manzoor, Justin T Puckett, Sachin Kamal-Bahl, Hasan Alhasani, Arliene Ravelo, Dureshahwar Jawaid, Jalpa A Doshi
The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the availability of Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Despite clinical trial data supporting these novel oral agents, evidence evaluating real-world adherence is limited. This study used 2015-2019 Medicare claims data for elderly patients with relapsed/refractory CLL to assess differences in real-world adherence and discontinuation in the 12 months after treatment initiation...
September 21, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37715316/ethnic-disparities-in-presentation-but-not-outcome-in-multiple-myeloma-patients-a-multicenter-retrospective-study-in-northern-israel
#5
JOURNAL ARTICLE
Najib Dally, Myriam Baranes, Luiza Akria, Marat Kashlikov, Khalil Tarabia, Adi Sharabi-Nov, Celia Suriu, Andrei Braester
Several studies showed ethnic disparities in multiple myeloma (MM) incidence and prognosis. In order to compare prognosis and overall survival between different ethnic groups, a multicenter retrospective study was conducted in Northern Israel. A total of 145 patients suffering from MM were included (72% Jewish, and 28% Arabs) who were treated between 2008-2018. A difference was found in the stage of the disease at the time of diagnosis, patients of Arab origin were diagnosed at a more advanced stage (III), (53...
September 15, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37715313/temporal-trend-in-survival-for-chronic-myelomonocytic-leukemia-in-the-us-a-population-based-study
#6
JOURNAL ARTICLE
Arnaud Lesegretain, Andrew Brunner, Aziz Benzohra, Amir T Fathi
Outcomes for chronic myelomonocytic leukemia (CMML) are insufficiently characterized at the population level. We analyzed epidemiological trends for patients between 2001 and 2017, focusing on age, sex, race, and long-term survivors. Using the Surveillance, Epidemiology, and End Results Program, we studied 3929 patients, in four time-period (tp) cohorts, based on year of diagnosis [2001-2004 (tp1); 2005-2009 (tp2); 2010-2013 (tp3); 2014-2017 (tp4)]. Stable incidence overall, male predominance, and higher incidence for White versus Black and 'Other' races were noted...
September 15, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37708450/embelin-inhibits-viability-of-cutaneous-t-cell-lymphoma-cell-lines-hut78-and-h9-by-targeting-inhibitors-of-apoptosis
#7
JOURNAL ARTICLE
Nabeel Abdulrahman, Rari Leo, Hasna Amal Boumenar, Fareed Ahmad, Jericha M Mateo, Anh Jochebeth, Naila Khalid Al-Sowaidi, Gulab Sher, Abdul W Ansari, Majid Alam, Shahab Uddin, Aamir Ahmad, Martin Steinhoff, Joerg Buddenkotte
Cutaneous T cell lymphoma (CTCL) is a varied group of neoplasms that affects the skin. Acquired resistance against chemotherapeutic drugs and associated toxic side effects are limitations that warrant search for novel drugs against CTCL. Embelin (EMB) is a naturally occurring benzoquinone derivative that has gained attention owing to its anticancer pharmacological actions and nontoxic nature. We assessed the anticancer activity of EMB against CTCL cell lines, HuT78, and H9. EMB inhibited viability of CTCL cells in a dose-dependent manner...
September 14, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37708442/chimeric-antigen-receptor-t-cell-immunotherapies-adverse-events-reported-to-faers-database-focus-on-cytopenias
#8
JOURNAL ARTICLE
Ainhoa Gomez-Lumbreras, Santiago Mercadal Vilchez, Lorenzo Villa-Zapata, Daniel C Malone, Daniel R Couriel
Chimeric antigen receptor (CAR) T-cell therapy presents a promising treatment for hematologic malignancies, displaying high efficacy but not being exempt from toxicity. In this observational study, we assessed adverse events (AEs) reported to the Food and Drug Adverse Event Reporting System (FAERS) including any of the six approved CAR T-cell therapies. A total of 5249 reports mentioning a CAR T-cell as a suspect product were retrieved from the FAERS database, containing a total of 24333 AEs, of which 3236 (13...
September 14, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37706519/preclinical-activity-of-a-novel-multi-axis-inhibitor-in-aggressive-and-indolent-b-cell-malignancies
#9
JOURNAL ARTICLE
Audrey L Smith, Dhananjaya Pal, Rolando Martinez-Rico, Alexandria P Eiken, Donald L Durden, Tatiana G Kutateladze, Dalia El-Gamal
No abstract text is available yet for this article.
September 14, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37706509/very-low-dose-radiotherapy-for-extranodal-marginal-zone-lymphoma-of-bronchus-associated-lymphoid-tissue
#10
JOURNAL ARTICLE
Morgan E Freret, Kathryn R Tringale, Lillian Boe, Brandon S Imber, Erel Joffe, Joachim Yahalom, Carla Hajj
Extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue (BALT) is a rare cancer for which optimal treatment strategies are undefined. Retrospective analyses suggest excellent outcomes with surgical resection for localized BALT lymphoma; however, the role of radiotherapy remains underexplored. We report the largest-to-date single-center analysis of 13 primary BALT lymphoma patients treated with radiotherapy. Of 15 treated lesions, we report a 100% response rate with complete response (CR) achieved in 67% of lesions...
September 14, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37706491/influence-of-treatment-intensity-and-medical-comorbidities-in-older-adults-with-peripheral-t-cell-lymphoma
#11
JOURNAL ARTICLE
Max J Gordon, Zhigang Duan, Hui Zhao, Loretta Nastoupil, Samuel Ng, Alexey V Danilov, Swaminathan Iyer, Sharon H Giordano
We conducted a population-based study of patients >65 years, diagnosed 2008-2017, with peripheral T-cell lymphoma (PTCL) using SEER-Medicare. Associations between PTCL subtype, treatment regimen, comorbidity, and mortality were assessed using the Kaplan-Meier method and multivariable Cox regression. Amongst the 2,546 patients, the median age was 77 years (interquartile range, 71-83). 5-year overall survival (OS) ranged from 22.2% to 37.3% depending on PTCL subtype. The most common frontline regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)...
September 14, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37698115/severe-chronic-primary-neutropenia-findings-from-a-patient-who-underwent-exstensive-evaluation-including-adenosine-deaminase-2-gene-variant-assessment
#12
JOURNAL ARTICLE
Katia Paciaroni, Eugenio Sangiorgi, Federica Pulvirenti, Nicoletta Villiva, Cristina Andrizzi, Selenia Campagna, Attilio Tordi, Francesca Celesti, Raffaele Manna, Fiorella Gurrieri, Stefano Licci, Tommaso Caravita di Toritto
No abstract text is available yet for this article.
September 12, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37690007/utility-of-routine-pulmonary-function-test-after-autologous-hematopoietic-cell-transplantation-in-lymphoma
#13
JOURNAL ARTICLE
Parastoo B Dahi, Sheila Kenny, Jessica Flynn, Sean M Devlin, Josel D Ruiz, Stephanie A Chinapen, Oscar B Lahoud, Matthew J Matasar, Craig H Moskowitz, Miguel-Angel Perales, Gunjan Shah, Craig S Sauter, Sergio A Giralt, Alexander I Geyer, Ann A Jakubowski
This study aims to evaluate the predictive value of routine pulmonary function testing (PFT) at the 12-month mark post-autologous hematopoietic cell transplant (AHCT) in identifying clinically significant lung disease in lymphoma survivors. In 247 patients, 173 (70%) received BEAM (carmustine, etoposide, cytarabine, melphalan), and 49 (20%) received TBC (thiotepa, busulfan, cyclophosphamide) conditioning regimens. Abnormal baseline PFT was noted in 149 patients (60%). Thirty-four patients had a significant decline (reduction of >/= 20% in DLCO or FEV1 or FVC) in post-AHCT PFT, with the highest incidence in the CNS lymphoma group (39%)...
September 10, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37689986/validation-of-imatinib-therapy-failure-score-imtf-in-chronic-phase-chronic-myeloid-leukemia-in-real-life-practice
#14
JOURNAL ARTICLE
Claudia Ielo, Emilia Scalzulli, Ida Carmosino, Sara Pepe, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival...
September 10, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37688482/recommendations-on-prevention-of-infections-in-patients-with-t-cell-lymphomas-a-narrative-review-and-synthesis
#15
REVIEW
Gemma Reynolds, Mary Ann Anderson, Karin Thursky, Benjamin W Teh, Monica A Slavin
T/Natural killer (NK) cell lymphomas (TCL) represent a heterogenous subgroup of non-Hodgkin lymphoma, associated with poorer prognosis and higher treatment toxicity. A cohesive synthesis of infection outcomes among TCL patients is lacking. International guidelines offer no specific recommendations regarding prophylaxis or supportive infection care for TCL patients. This systematic narrative review highlights infection outcomes in TCL patients treated with conventional, and novel therapies. Recommendations for infection screening, antimicrobial prophylaxis and vaccination strategies are outined...
September 9, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37683053/gene-expression-and-copy-number-profiling-of-follicular-lymphoma-biopsies-from-patients-treated-with-first-line-rituximab-without-chemotherapy
#16
JOURNAL ARTICLE
E Leich, Marianne Brodtkorb, T Schmidt, M Altenbuchinger, Ole Christian Lingjærde, S Lockmer, H Holte, T Nedeva, T Grieb, B Sander, C Sundström, R Spang, E Kimby, A Rosenwald
The Nordic Lymphoma Study Group has performed two randomized clinical trials with chemotherapy-free first-line treatment (rituximab +/- interferon) in follicular lymphoma (FL), with 73% of patients alive and 38% without any need of chemotherapy after 10.6 years median follow-up. In order to identify predictive markers, that may also serve as therapeutic targets, gene expression- and copy number profiles were obtained from 97 FL patients using whole genome microarrays. Copy number alterations (CNAs) were identified, e...
September 8, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37680012/treatment-patterns-resource-utilization-and-clinical-outcomes-in-patients-with-higher-risk-myelodysplastic-syndromes-mds-in-united-states-community-practices
#17
JOURNAL ARTICLE
Shanna Arnold Egloff, Xiting Cao, Rebecca Lachs, Casey Martin, Meredith Mattlin, Emma Fennell, Dillan Rayburn, Daniel Schlauch, Dax Kurbegov, Susan Ide, Minoo Battiwalla
Management of higher-risk myelodysplastic syndromes (HR-MDS) is challenging in the real world. We studied 200 patients with HR-MDS within a large US community hospital network. We describe the clinical presentation, patient-related factors, prognostic characteristics, treatment patterns, clinical outcomes and resource utilization. Patients with HR-MDS, treated in our community setting, were elderly (median age 76 years) with a high comorbidity burden. First-line therapy was hypomethylating agent (HMA) monotherapy (20%), lenalidomide (2%), and venetoclax (2%), while the rest were treated with supportive care...
September 7, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37680001/allogeneic-hematopoietic-stem-cell-transplantation-in-adults-with-dendritic-histiocytic-neoplasms
#18
JOURNAL ARTICLE
Charles Gaulin, Fiona Craig, Shannon Fortin Ensign, Ryan Robetorye, Sarah Gibson, Katalin Kelemen, Nandita Khera, Jose Leis, Mazie Tsang, Allison Rosenthal, Javier Munoz, Jeanne Palmer, Talal Hilal
No abstract text is available yet for this article.
September 7, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37674433/immune-reconstitution-inflammatory-syndrome-in-a-patient-with-m-haemophilum-infection-after-allogeneic-hematopoietic-stem-cell-transplantation
#19
JOURNAL ARTICLE
Markus Plate, Jose Jessurun, Koen van Besien
No abstract text is available yet for this article.
September 7, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37674391/characteristics-and-therapeutic-approaches-for-patients-diagnosed-with-t-all-lbl-exhibiting-t-8-14-q24-q11-tcra-d-myc-translocation
#20
JOURNAL ARTICLE
Xian Zhang, Tong Wang, Yang Zhang, Fang Wang, Jiaqi Chen, Jingbo Ni, Ruijuan Sun, Zhijie Wei, Gailing Zhang, Wenqian Li, Jingjing Li, Peihua Lu
T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) patients with t(8;14)(q24;q11)/TCRA/D::MYC translocation represent a rare subgroup, with an aggressive course. In our retrospective analysis of 14 patients, all were identified during refractory or relapsed stages (5 primary tumor, 9 relapse). Notably, extramedullary invasion was detected in most patients. Four exhibited STIL::TAL1 translocation, and six demonstrated CDKN2A/B gene loss. The therapeutic outcomes were notably poor for all seven patients who received only chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT); all eventually succumbed to the disease with a median OS of 3 months...
September 7, 2023: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.